Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer

Molecular Carcinogenesis

Volumn 52, Issue 6, 2013, Pages 475-487

  Alvarez, Carolina ^a   Tapia, Teresa ^a   Cornejo, Valeria ^b   Fernandez, Wanda ^b   Muñoz, Alex ^c   Camus, Mauricio ^d   Alvarez, Manuel ^e   Devoto, Luigi ^c   Carvallo, Pilar ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e CLÍNICA LAS CONDES   (Chile)

Author keywords

Biopsies; BRCAX; Hereditary breast cancer; Promoter hypermethylation; Protein expression; Tumor suppressor gene

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; MEMBRANE PROTEIN; PROGESTERONE RECEPTOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SLIT2 PROTEIN; UNCLASSIFIED DRUG; WIF1 PROTEIN;

ARTICLE; BREAST BIOPSY; BREAST CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CPG ISLAND; GENE FREQUENCY; GENETIC DISORDER; GENETIC SCREENING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BASE SEQUENCE; BREAST; BREAST NEOPLASMS; DNA; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVE TISSUE PROTEINS; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84876453305     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21881     Document Type: Article

References (45)

1. DEIS. Departamento de Estadísticas e Información de Salud, Ministerio de Salud de Chile. http://deis.minsal.cl/index.asp
2. Knudson AG. Hereditary cancer: Two hits revisited. J Cancer Res Clin Oncol 1996; 122: 135- 140.
3. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225- 3229.
4. Burbee DG, Forgacs E, Zöchbauer-Müller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93: 691- 699.
5. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25: 315- 319.
6. Rong R, Jin W, Zhang J, Sheikh MS, Huang Y. Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest. Oncogene 2004; 23: 8216- 8230.
7. Ye M, Xia B, Guo Q, Zhou F, Zhang X. Association of diminished expression of RASSF1A with promoter methylation in primary gastric cancer from patients of central China. BMC Cancer 2007; 7: 120.
8. Brose K, Bland KS, Wang KH, et al. Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell 1999; 96: 795- 806.
9. Dallol A, Da Silva NF, Viacava P, et al. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 2002; 62: 5874- 5880.
10. Strickland P, Shin GC, Plump A, Tessier-Lavigne M, Hinck L. Slit2 and netrin 1 act synergistically as adhesive cues to generate tubular bi-layers during ductal morphogenesis. Development 2006; 133: 823- 832.
11. Wu JY, Feng L, Park HT, et al. The neuronal repellent Slit inhibits leukocyte chemotaxis induced by chemotactic factors. Nature 2001; 410: 948- 952.
12. Hsieh JC, Kodjabachian L, Rebbert ML, et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999; 398: 431- 436.
13. Wissmann C, Wild PJ, Kaiser S, et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003; 201: 204- 212.
14. Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004; 64: 4717- 4720.
15. Taniguchi H, Yamamoto H, Hirata T, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005; 24: 7946- 7952.
16. Urakami S, Shiina H, Enokida H, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res 2006; 12: 383- 391.
17. Chen Y, Zhou J, Xu Y, et al. BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer. Cancer Sci 2009; 100: 1663- 1667.
18. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006; 8: R38.
19. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000; 21: 1761- 1765.
20. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: Relationship to gene expression profiles. Breast Cancer Res Treat 2005; 91: 179- 186.
21. Tapia T, Smalley SV, Kohen P, et al. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics 2008; 3: 157- 163.
22. Parrella P, Poeta ML, Gallo AP, et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 2004; 10: 5349- 5354.
23. Jing F, Zhang J, Tao J, et al. Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. Onkologie 2007; 30: 14- 19.
24. Vallian S, Sedaghat M, Nassiri I, Frazmand A. Methylation status of p16 INK4A tumor suppressor gene in Iranian patients with sporadic breast cancer. J Cancer Res Clin Oncol 2009; 135: 991- 996.
25. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 10: 3001- 3007.
26. Ai L, Tao Q, Zhong S, et al. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 2006; 27: 1341- 1348.
27. Sharma G, Mirza S, Prasad CP, Srivastava A, Gupta SD, Ralhan R. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and SLIT2 in serum and tumor DNA from breast cancer patients. Life Sci 2007; 80: 1873- 1881.
28. Vasilatos SN, Broadwater G, Barry WT, et al. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 2009; 18: 901- 914.
29. Antill YC, Mitchell G, Johnson SA, et al. Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010; 19: 265- 274.
30. Gallardo M, Silva A, Rubio L, et al. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Breast Cancer Res Treat 2006; 95: 81- 87.
31. Clarke S, Statham A, Stirzaker C, Molloy P, Frommer M. DNA methylation: Bisulphite modification and analysis. Nat Protoc 2006; 1: 2353- 2364.
32. Herman J, Graft J, Myöhänen S, Nelkin B, Baylin S. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci 1996; 93: 9821- 9826.
33. Li Y, Wei Q, Cao F, Cao X. Expression and promoter methylation of the RASSF1A gene in sporadic breast cancers in Chinese women. Oncol Rep 2008; 19: 1149- 1153.
34. Pfeifer GP, Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc) 2005; 70: 576- 583.
35. Karray-Chouayekh S, Trifa F, Khabir A, et al. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients. J Cancer Res Clin Oncol 2010; 136: 203- 210.
36. Lehmann U, Länger F, Feist H, Glöckner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002; 160: 605- 612.
37. Pasquali L, Bedeir A, Ringquist S, Styche A, Bhargava R, Trucco G. Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma. Cancer Lett 2007; 257: 136- 144.
38. Sunami E, Shinozaki M, Sim MS, et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 2008; 10: R46.
39. Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005; 24: 7946- 7952.
40. Licchesi JD, Van Neste L, Tiwari VK, et al. Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc. Oncogene 2010; 29: 5923- 5934.
41. Astuti D, Da Silva NF, Dallol A, et al. SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma. Br J Cancer 2004; 90: 515- 521.
42. Dunwell TL, Dickinson RE, Stankovic T, et al. Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia. Epigenetics 2009; 4: 265- 269.
43. Jin J, You H, Yu B, et al. Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas. Biochem Biophys Res Commun 2009; 379: 86- 91.
44. Xian J, Aitchison A, Bobrow L, et al. Targeted disruption of the 3p12 gene, Dutt1/Robo1, predisposes mice to lung adenocarcinomas and lymphomas with methylation of the gene promoter. Cancer Res 2004; 64: 6432- 6437.
45. Narayan G, Goparaju C, Arias-Pulido H, et al. Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer 2006; 5: 16.